On January 30, the Ministry of industry and information technology and other nine departments jointly issued the “14th five year plan” for the development of pharmaceutical industry. The plan puts forward the development goals for the next five years and the long-term goals for the next 15 years. By 2025, the main economic indicators will achieve medium and high-speed growth, outstanding innovation achievements in frontier fields, enhanced innovation driving force, significantly improved the modernization level of industrial chain, further improved the supply guarantee system of pharmaceutical machinery, and comprehensively moved towards high-end internationalization
define six development goals
In order to achieve the development goals, the plan puts forward six specific goals.
In terms of benefits, during the “14th five year plan” period, the average annual growth rate of operating revenue and total profit of the pharmaceutical industry remained above 8%, the proportion of added value in all industries increased to about 5%, and the concentration of leading enterprises in the industry further increased.
In terms of innovation, the R & D investment of the whole industry has increased by more than 10% annually; By 2025, the proportion of new sales of innovative products in the increment of operating revenue of the whole industry will further increase.
In terms of industrial chain and supply chain, the advantages of large-scale and systematic pharmaceutical manufacturing have been further consolidated, a number of key common technologies for industrialization have made breakthroughs, and positive results have been achieved in making up for weaknesses in key fields, so as to cultivate and form a number of key enterprises with leading and driving ability of industrial ecology in subdivided fields.
In terms of supply guarantee, the supply of drugs, vaccines, protective materials and diagnosis and treatment equipment for major diseases is sufficient, and the medical reserve system has been improved; The supply of essential drugs, minor drugs and drugs that are easy to be in short supply is stable, and the guarantee ability of a number of clinically urgently needed drugs for children and rare diseases is enhanced.
In terms of improving the manufacturing level, the quality management of drugs and medical devices in the whole life cycle has been strengthened, and the number of generic drugs passing the consistency evaluation has further increased; The development level of green, digital and intelligent enterprises has been significantly improved, the safety technology and management level have been effectively improved, and the ability of production safety risk management and control has been significantly enhanced.
In terms of international development, the export volume of medicine has maintained growth; Breakthrough in “going out” of Chinese patent medicine; Cultivate a number of world-famous brands; A number of large pharmaceutical companies with global layout of R & D and production and high proportion of international sales have been formed.
Looking forward to 2035, China Meheco Group Co.Ltd(600056) industrial strength will achieve an overall leap; The innovation driven development pattern has been fully formed, and the number of original new drugs and “leading” products has increased, becoming an important source of world pharmaceutical innovation; Prominent industrial competitive advantages and upgrading of industrial structure occupy an important position in the global pharmaceutical industry chain; With a wide range of products and excellent quality, we can achieve a higher level to meet the health needs of the people and provide a solid guarantee for building a healthy China in an all-round way
clarify five key tasks
Focusing on the development objectives, the plan puts forward five key tasks to be implemented during the 14th Five Year Plan period. Combined with the technological development trend, the plan puts forward five major projects in the form of columns, such as the industrialization project of pharmaceutical innovative products, the tackling project of pharmaceutical industrialization technology, the guarantee project of vaccine and shortage drug supply, the product quality upgrading project and the green and low-carbon project of pharmaceutical industry.
The plan proposes to speed up product innovation and technological breakthroughs in industrialization. First, strengthen key core technology research, vigorously promote innovative product research and development, and improve the level of industrialization technology. Second, promote the industrialization and application of innovative drugs and high-end medical devices, accelerate the industrialization process of new products, and promote the promotion and application of innovative products. Third, improve the pharmaceutical innovation support system, strengthen the technical cooperation between industry, University, research and medicine, improve the professional R & D service ability, and create a good environment for encouraging innovation.
The plan proposes to improve the stability and competitiveness of the industrial chain. First, make up for the shortcomings of the industrial chain, tackle key technical products, deeply carry out “one-stop” application demonstration of key products and processes, and improve government procurement, first set, first batch and other policies. The second is to enhance the advantages of the industrial chain, encourage enterprises to continuously strengthen the advantages of systematic manufacturing, consolidate the advantages of API manufacturing, create the integration advantages of “API + Preparation”, and encourage the industrial technology development of biological drugs. Third, cultivate high-quality market players in different fields, implement the cultivation project of pharmaceutical pilot enterprises, and support the development of specialized and new “little giant” enterprises. Fourth, optimize the regional layout of the industrial chain, focus on supporting the development of about 10 cities as the main engine of new industrial momentum, and focus on supporting the development of national medicine industry in about 7 ethnic minority areas.
The plan also proposes to enhance the supply guarantee capacity; Promote the upgrading of pharmaceutical manufacturing capacity system; Create new advantages in international competition
domestic innovative drugs enter the golden harvest period
Shanxi Securities Co.Ltd(002500) believes that domestic innovative drugs have entered the golden harvest period and gradually opened the road of internationalization and upgrading. With an endless stream of incentive policies, the reform of the examination and approval system, and the continuous increase of investment in talents and R & D, China’s innovative drugs have ushered in the spring of development. After many years of rapid development, China has established a local innovation ecosystem. In order to seek greater R & D returns, enterprises have begun to adopt license out (overseas authorization) and independent development mode to integrate with the international market and open up the era of internationalization. In addition, the development of innovative drugs in China has experienced from scratch and blind homogeneous competition, and has entered a new upgrading stage, gradually transforming to me better / best and first in class. In the process of industrial upgrading, in the future, whether in the Chinese market or overseas market, pharmaceutical enterprises need to make differentiated and clinically valuable innovations in terms of targets and indications. Only enterprises with real innovation strength can gain a foothold in the industry.
Shanxi Securities Co.Ltd(002500) said that the overall development of the pharmaceutical industry is good, the traditional generic pharmaceutical industry continues to be under pressure, and innovation is still the main theme of development. The research and development of innovative drugs in the world and China is booming, and new discoveries, new technologies and new fields are emerging, accelerating the rapid development of industry and industrial chain. It is suggested to actively pay attention to the marginal changes of industrial policies, the changes of product competition pattern of relevant enterprises and the value of R & D pipelines.
Founder Securities Co.Ltd(601901) it is suggested to pay attention to the following main investment lines: it is optimistic that high-end medical equipment will benefit from the improvement of new infrastructure demand and the acceleration of domestic substitution; The spring breeze of rehabilitation medical service policy drives the growth of demand for rehabilitation equipment; The life science research track has a high boom, and the industry has a long slope and thick snow. We are optimistic about the water delivery people of the scientific research track; IVD China’s centralized purchase expectation suppresses the valuation and is optimistic about the new increment brought by the strong ability to go to sea and the acceleration of overseas marketing network construction; The prosperity of CXO industry continues, and the transfer of global share and the expansion of Chinese production capacity help Chinese enterprises become the first tier in the world; The value of the manufacturing industry chain moves upstream, and the concentration of API head enterprises is expected to be further improved; The valuation of innovative drugs has fallen, the difficulty of financing has increased, the survival of the fittest in the industry has been promoted, and high-quality enterprises with strong commercialization and internationalization ability have been selected; The national policy strongly encourages the development of traditional Chinese medicine, the completion of the pilot of traditional Chinese medicine formula granules, and the implementation of the national standard to drive the volume and price rise.
